TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Prospective, Randomized, Double-blind, Multicenter Trial on the Effects of the Early Femoral Nerve Block in Elderly With Hip Fracture
Brief Summary: Assess if the addition of an early femoral nerve block (performed within 2 hours from the admission in emergency department through a femoral nerve catheter) in the elderly patients (\> 70 years) with hip fracture, reduces the incidence of postoperative delirium assessed by CAM 3Ds test, compared to the traditional systemic pain therapy.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Device: Ultrasound guided fascia iliaca compartment block, Drug: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms) | Arm Label: Bupivacaine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bupivacaine, Device: Ultrasound guided fascia iliaca compartment block, Drug: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Bupivacaine; Assigned to Arm(s): Bupivacaine | Intervention Type: DEVICE; Name: Ultrasound guided fascia iliaca compartment block; Assigned to Arm(s): Bupivacaine, Placebo | Intervention Type: DRUG; Name: Intrathecal medications (bupivacaine (15 mg) in conjunction with fentanyl 20 micrograms); Assigned to Arm(s): Bupivacaine, Placebo
B: Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Fascia iliaca block; Type: EXPERIMENTAL; Interventions: Procedure: Fascia iliaca block arm | Intervention Type: PROCEDURE; Name: Fascia iliaca block arm; Assigned to Arm(s): Fascia iliaca block
C: Arm Label: femoral group; Type: ACTIVE_COMPARATOR; Interventions: Procedure: femoral nerve catheter, Drug: femoral group | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Procedure: femoral nerve catheter, Drug: control group | Intervention Type: PROCEDURE; Name: femoral nerve catheter; Assigned to Arm(s): control group, femoral group | Intervention Type: DRUG; Name: femoral group; Assigned to Arm(s): femoral group | Intervention Type: DRUG; Name: control group; Assigned to Arm(s): control group
D: Arm Label: fascia iliaca compartment block; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ropivacaine, Device: Ultrasound | Arm Label: intravenous fentanyl; Type: ACTIVE_COMPARATOR; Interventions: Drug: Fentanyl | Intervention Type: DRUG; Name: Ropivacaine; Assigned to Arm(s): fascia iliaca compartment block | Intervention Type: DRUG; Name: Fentanyl; Assigned to Arm(s): intravenous fentanyl | Intervention Type: DEVICE; Name: Ultrasound; Assigned to Arm(s): fascia iliaca compartment block

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Brief Summary: This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. Its primary objective is to assess whether adding bevacizumab to ixabepilone improves progression-free survival in its target population. Study participants will be stratified by (a) study site and (b) previous receipt of bevacizumab prior to randomization.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Paclitaxel, Drug: AMG 386 Placebo, Drug: Carboplatin | Arm Label: AMG 386; Type: ACTIVE_COMPARATOR; Interventions: Drug: AMG 386, Drug: Paclitaxel, Drug: Carboplatin | Intervention Type: DRUG; Name: AMG 386; Assigned to Arm(s): AMG 386 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): AMG 386, Placebo | Intervention Type: DRUG; Name: AMG 386 Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): AMG 386, Placebo
B: Arm Label: Farletuzumab; Type: EXPERIMENTAL; Interventions: Drug: Farletuzumab | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Farletuzumab; Assigned to Arm(s): Farletuzumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab
D: Arm Label: Trabectedin; Type: EXPERIMENTAL; Interventions: Drug: Trabectedin | Arm Label: Dacarbazine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dacarbazine | Intervention Type: DRUG; Name: Trabectedin; Assigned to Arm(s): Trabectedin | Intervention Type: DRUG; Name: Dacarbazine; Assigned to Arm(s): Dacarbazine

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Brief Summary: This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. Its primary objective is to assess whether adding bevacizumab to ixabepilone improves progression-free survival in its target population. Study participants will be stratified by (a) study site and (b) previous receipt of bevacizumab prior to randomization.


Options:
A: Arm Label: DNIB0600A; Type: EXPERIMENTAL; Interventions: Drug: DNIB0600A | Arm Label: PLD; Type: ACTIVE_COMPARATOR; Interventions: Drug: PLD | Intervention Type: DRUG; Name: DNIB0600A; Assigned to Arm(s): DNIB0600A | Intervention Type: DRUG; Name: PLD; Assigned to Arm(s): PLD
B: Arm Label: Carboplatin and gemcitabine + bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Bevacizumab | Arm Label: Carboplatin and gemcitabine + placebo; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Gemcitabine, Drug: Placebo | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab, Carboplatin and gemcitabine + placebo | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Carboplatin and gemcitabine + bevacizumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Carboplatin and gemcitabine + placebo
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Vandetanib | Intervention Type: DRUG; Name: Vandetanib; Assigned to Arm(s): 1
D: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized Phase II Evaluation of Weekly Ixabepilone With or Without Biweekly Bevacizumab in Recurrent or Persistent Platinum-resistant/Refractory Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers
Brief Summary: This is a randomized, two-arm, open-label Phase II multicenter study designed to examine the effects of adding bevacizumab to ixabepilone for the treatment of patients who have recurrent or persistent platinum-resistant/refractory epithelial (non-mucinous) ovarian, fallopian tube, or primary peritoneal cancer. Its primary objective is to assess whether adding bevacizumab to ixabepilone improves progression-free survival in its target population. Study participants will be stratified by (a) study site and (b) previous receipt of bevacizumab prior to randomization.


Options:
A: Arm Label: experimental group; Type: EXPERIMENTAL; Interventions: Drug: apatinib | Arm Label: control group; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebos | Intervention Type: DRUG; Name: apatinib; Assigned to Arm(s): experimental group | Intervention Type: DRUG; Name: Placebos; Assigned to Arm(s): control group
B: Arm Label: Ixabepilone; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ixabepilone | Arm Label: Ixabepilone + Bevacizumab; Type: EXPERIMENTAL; Interventions: Drug: Ixabepilone, Drug: Bevacizumab | Intervention Type: DRUG; Name: Ixabepilone; Assigned to Arm(s): Ixabepilone, Ixabepilone + Bevacizumab | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Ixabepilone + Bevacizumab
C: Arm Label: Tivozanib; Type: EXPERIMENTAL; Interventions: Drug: Tivozanib | Arm Label: Standard Care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DRUG; Name: Tivozanib; Assigned to Arm(s): Tivozanib
D: Arm Label: Arm 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Niraparib | Arm Label: Arm 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: Paclitaxel, Drug: Bevacizumab, Drug: Niraparib | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Paclitaxel; Assigned to Arm(s): Arm 1, Arm 2 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Arm 2 | Intervention Type: DRUG; Name: Niraparib; Assigned to Arm(s): Arm 1, Arm 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 3 Study in Subjects With Relapsing Remitting Multiple Sclerosis to Evaluate the Tolerability of ALKS 8700 and Dimethyl Fumarate
Brief Summary: The objectives of this study are to evaluate the utility of two gastrointestinal (GI) symptom scales (Individual GI Symptom and Impact Scale {IGISIS} and Global GI Symptom and Impact Scale {GGISIS}) in assessing GI tolerability in adult subjects with RRMS after administration of ALKS 8700 or Dimethyl Fumarate (DMF) in Part A, to compare the GI tolerability of ALKS 8700 and DMF in adult subjects with RRMS using IGISIS and GGISIS in Part B, and to Evaluate the safety and tolerability of ALKS 8700 in adult subjects with RRMS in Parts A and B.


Options:
A: Arm Label: ALKS 8700; Type: EXPERIMENTAL; Interventions: Drug: ALKS 8700 | Arm Label: Dimethyl Fumarate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dimethyl Fumarate | Intervention Type: DRUG; Name: ALKS 8700; Assigned to Arm(s): ALKS 8700 | Intervention Type: DRUG; Name: Dimethyl Fumarate; Assigned to Arm(s): Dimethyl Fumarate
B: Arm Label: Interferon beta-1a; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon beta-1a, Drug: Placebo to ozanimod | Arm Label: Ozanimod 0.5 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Arm Label: Ozanimod 1 mg; Type: EXPERIMENTAL; Interventions: Drug: Ozanimod, Drug: Placebo to interferon beta-1a | Intervention Type: DRUG; Name: Ozanimod; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg | Intervention Type: DRUG; Name: Interferon beta-1a; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to ozanimod; Assigned to Arm(s): Interferon beta-1a | Intervention Type: DRUG; Name: Placebo to interferon beta-1a; Assigned to Arm(s): Ozanimod 0.5 mg, Ozanimod 1 mg
C: Arm Label: Rebif® New Formulation (IFN-beta-1a, RNF); Type: EXPERIMENTAL; Interventions: Drug: Rebif® New Formulation (IFN-beta-1a, RNF) | Arm Label: Placebo/RNF; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Rebif® New Formulation (IFN-beta-1a, RNF) | Intervention Type: DRUG; Name: Rebif® New Formulation (IFN-beta-1a, RNF); Assigned to Arm(s): Rebif® New Formulation (IFN-beta-1a, RNF) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo/RNF | Intervention Type: DRUG; Name: Rebif® New Formulation (IFN-beta-1a, RNF); Assigned to Arm(s): Placebo/RNF
D: Arm Label: Laquinimod 0.3 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: laquinimod 0.3 | Arm Label: Laquinimod 0.6 mg; Type: ACTIVE_COMPARATOR; Interventions: Drug: laquinimod 0.6 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DRUG; Name: laquinimod 0.3; Assigned to Arm(s): Laquinimod 0.3 mg | Intervention Type: DRUG; Name: laquinimod 0.6; Assigned to Arm(s): Laquinimod 0.6 mg | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind, Placebo-Controlled, Parallel Study to Evaluate Safety, Pharmacokinetics (PK) and Pharmacodynamics(PD) of FDL169 in Cystic Fibrosis (CF) Subjects Homozygous for the F508del-CFTR Mutation
Brief Summary: This is a multicenter, randomized, placebo-controlled, dose-escalation study. Enrollment is planned to occur at approximately 14 global sites. Approximately 24 subjects with CF.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: LUM 600 mg qd/IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination, Drug: Ivacaftor | Arm Label: LUM 400 mg q12h/ IVA 250 mg q12h; Type: EXPERIMENTAL; Interventions: Drug: Lumacaftor Plus Ivacaftor Combination | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: Lumacaftor Plus Ivacaftor Combination; Assigned to Arm(s): LUM 400 mg q12h/ IVA 250 mg q12h, LUM 600 mg qd/IVA 250 mg q12h | Intervention Type: DRUG; Name: Ivacaftor; Assigned to Arm(s): LUM 600 mg qd/IVA 250 mg q12h
B: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA
C: Arm Label: FDL 169 test formulation (Dose Level 1); Type: EXPERIMENTAL; Interventions: Drug: FDL169 | Arm Label: FDL 169 test formulation (Dose Level 2); Type: EXPERIMENTAL; Interventions: Drug: FDL169 | Arm Label: FDL 169 test formulation ( Dose Level 3); Type: EXPERIMENTAL; Interventions: Drug: FDL169 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: FDL169; Assigned to Arm(s): FDL 169 test formulation ( Dose Level 3), FDL 169 test formulation (Dose Level 1), FDL 169 test formulation (Dose Level 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: ELX/TEZ/IVA; Type: EXPERIMENTAL; Interventions: Drug: ELX/TEZ/IVA, Drug: IVA | Intervention Type: DRUG; Name: ELX/TEZ/IVA; Assigned to Arm(s): ELX/TEZ/IVA | Intervention Type: DRUG; Name: IVA; Assigned to Arm(s): ELX/TEZ/IVA

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window: a Randomized, Controlled Trial
Brief Summary: TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of symptom onset). Up to 665 subjects will be randomized. Primary endpoint will be functional outcome assessed by the modified Rankin scale at 90 days post-stroke ("mRS shift analysis"). By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute stroke population with uncertain benefit of endovascular stroke treatment.


Options:
A: Arm Label: Best medical management.; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Additional intra-arterial treatment.; Type: EXPERIMENTAL; Interventions: Other: Intra-arterial treatment | Intervention Type: OTHER; Name: Intra-arterial treatment; Assigned to Arm(s): Additional intra-arterial treatment.
B: Intervention Type: DRUG; Name: rt-PA 0.9 mg/kg verum or placebo Intravenous; Assigned to Arm(s): N/A
C: Arm Label: Low-dose rtPA (Recruitment completed in August 2015); Type: EXPERIMENTAL; Interventions: Drug: Low-dose rtPA | Arm Label: Standard-dose rtPA (Recruitment completed in August 2015); Type: ACTIVE_COMPARATOR; Interventions: Drug: Standard-dose rtPA | Arm Label: Early intensive BP lowering; Type: EXPERIMENTAL; Interventions: Other: Intensive blood pressure (BP) lowering | Arm Label: Control / guideline-based BP management; Type: ACTIVE_COMPARATOR; Interventions: Other: BP management policies | Intervention Type: DRUG; Name: Low-dose rtPA; Assigned to Arm(s): Low-dose rtPA (Recruitment completed in August 2015) | Intervention Type: DRUG; Name: Standard-dose rtPA; Assigned to Arm(s): Standard-dose rtPA (Recruitment completed in August 2015) | Intervention Type: OTHER; Name: Intensive blood pressure (BP) lowering; Assigned to Arm(s): Early intensive BP lowering | Intervention Type: OTHER; Name: BP management policies; Assigned to Arm(s): Control / guideline-based BP management
D: Arm Label: Thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Thrombectomy | Arm Label: Best medical care; Type: OTHER; Interventions: Other: Best medical care | Intervention Type: DEVICE; Name: Thrombectomy; Assigned to Arm(s): Thrombectomy | Intervention Type: OTHER; Name: Best medical care; Assigned to Arm(s): Best medical care

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy and Safety of Thrombectomy in Stroke With Extended Lesion and Extended Time Window: a Randomized, Controlled Trial
Brief Summary: TENSION (Efficacy and safety of ThrombEctomy iN Stroke with extended leSION and extended time window) is a prospective, open label, blinded endpoint (PROBE), European two-arm, randomized, controlled, post-market study to compare the safety and effectiveness of endovascular thrombectomy as compared to best medical care alone in the treatment of acute ischemic stroke patients with extended stroke lesions defined by an Alberta Stroke Program Early CT Score (ASPECTS) score of 3-5 and in an extended time window (up to 12 hours or unknown time of symptom onset). Up to 665 subjects will be randomized. Primary endpoint will be functional outcome assessed by the modified Rankin scale at 90 days post-stroke ("mRS shift analysis"). By this, TENSION will provide evidence of efficacy and safety of thrombectomy in an acute stroke population with uncertain benefit of endovascular stroke treatment.


Options:
A: Arm Label: Alteplase; Type: EXPERIMENTAL; Interventions: Drug: Tissue-type plasminogen activator (alteplase) | Arm Label: Standard Care; Type: OTHER; Interventions: Other: Standard care | Intervention Type: DRUG; Name: Tissue-type plasminogen activator (alteplase); Assigned to Arm(s): Alteplase | Intervention Type: OTHER; Name: Standard care; Assigned to Arm(s): Standard Care
B: Arm Label: intravenous tissue plasminogen activator; Type: EXPERIMENTAL; Interventions: Drug: Alteplase | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Alteplase; Assigned to Arm(s): intravenous tissue plasminogen activator | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Thrombectomy; Type: ACTIVE_COMPARATOR; Interventions: Device: Thrombectomy | Arm Label: Best medical care; Type: OTHER; Interventions: Other: Best medical care | Intervention Type: DEVICE; Name: Thrombectomy; Assigned to Arm(s): Thrombectomy | Intervention Type: OTHER; Name: Best medical care; Assigned to Arm(s): Best medical care
D: Arm Label: Best medical therapy; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: Endovascular treatment; Type: EXPERIMENTAL; Interventions: Device: Endovascular Mechanical Thrombectomy | Intervention Type: DEVICE; Name: Endovascular Mechanical Thrombectomy; Assigned to Arm(s): Endovascular treatment

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Chinese PLA Generation Hospital
Brief Summary: Background: Malignant peritoneal adhesion is a common complication and prognostic factor of ovarian cancer and other primary abdominal tumors. The incidence of peritoneal adhesion in advanced primary peritoneal tumor is 32-56%, which has increased by more than 10 times in the recent decade. Malignant peritoneal adhesion is closely associated with the morbidity and mortality of malignant intestinal obstruction. The peritoneal adhesion may aggravates the abdominal symptoms and reduce quality of life. Further, the peritoneal adhesion may impede treatment of primary tumor, such as operation or chemotherapy, lead to a poor prognosis.

Objective: This study aims to treat malignant peritoneal adhesion with the combination of antiangiogenic agent and chemotherapy, evaluate the efficacy and safety of intraperitoneal antiangiogenic agent plus chemotherapy. As explosive endpoints, we will examination the expression of VEGF-A in peritoneal cavity during the treatment.


Options:
A: Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Pazopanib | Intervention Type: DRUG; Name: Pazopanib; Assigned to Arm(s): Pazopanib | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Olaratumab and Liposomal Doxorubicin; Type: EXPERIMENTAL; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Arm Label: Liposomal Doxorubicin: Optional Olaratumab Monotherapy; Type: ACTIVE_COMPARATOR; Interventions: Biological: Olaratumab, Drug: liposomal doxorubicin | Intervention Type: BIOLOGICAL; Name: Olaratumab; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin | Intervention Type: DRUG; Name: liposomal doxorubicin; Assigned to Arm(s): Liposomal Doxorubicin: Optional Olaratumab Monotherapy, Olaratumab and Liposomal Doxorubicin
C: Arm Label: Intraperitoneal bevacizumab+ carboplatin; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Carboplatin, Drug: paclitaxel | Arm Label: Intraperitoneal carboplatin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Carboplatin, Drug: paclitaxel | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin | Intervention Type: DRUG; Name: Carboplatin; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin | Intervention Type: DRUG; Name: paclitaxel; Assigned to Arm(s): Intraperitoneal bevacizumab+ carboplatin, Intraperitoneal carboplatin
D: Arm Label: gemcitabine; Type: ACTIVE_COMPARATOR; Interventions: Drug: Gemcitabine | Arm Label: Gemcitabine + pazopanib; Type: EXPERIMENTAL; Interventions: Drug: Gemcitabine, Drug: pazopanib | Intervention Type: DRUG; Name: Gemcitabine; Assigned to Arm(s): Gemcitabine + pazopanib, gemcitabine | Intervention Type: DRUG; Name: pazopanib; Assigned to Arm(s): Gemcitabine + pazopanib

Answer: C